- Home
- ENVB vs KXIN Comparison
ENVB vs KXIN Comparison
Compare ENVB & KXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- KXIN
- Stock Information
- Founded
- ENVB 1994
- KXIN 2015
- Country
- ENVB United States
- KXIN China
- Employees
- ENVB N/A
- KXIN N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- KXIN Retail-Auto Dealers and Gas Stations
- Sector
- ENVB Health Care
- KXIN Consumer Discretionary
- Exchange
- ENVB Nasdaq
- KXIN Nasdaq
- Market Cap
- ENVB 3.3M
- KXIN 2.8M
- IPO Year
- ENVB N/A
- KXIN N/A
- Fundamental
- Price
- ENVB $1.36
- KXIN $1.28
- Analyst Decision
- ENVB
- KXIN
- Analyst Count
- ENVB 0
- KXIN 0
- Target Price
- ENVB N/A
- KXIN N/A
- AVG Volume (30 Days)
- ENVB 564.4K
- KXIN 266.9K
- Earning Date
- ENVB 03-25-2025
- KXIN 01-01-0001
- Dividend Yield
- ENVB N/A
- KXIN N/A
- EPS Growth
- ENVB N/A
- KXIN N/A
- EPS
- ENVB N/A
- KXIN N/A
- Revenue
- ENVB N/A
- KXIN $12,679,000.00
- Revenue This Year
- ENVB N/A
- KXIN N/A
- Revenue Next Year
- ENVB N/A
- KXIN N/A
- P/E Ratio
- ENVB N/A
- KXIN N/A
- Revenue Growth
- ENVB N/A
- KXIN N/A
- 52 Week Low
- ENVB $1.26
- KXIN $1.20
- 52 Week High
- ENVB $657.00
- KXIN $29.52
- Technical
- Relative Strength Index (RSI)
- ENVB 16.91
- KXIN 39.34
- Support Level
- ENVB $1.26
- KXIN $1.21
- Resistance Level
- ENVB $1.70
- KXIN $1.44
- Average True Range (ATR)
- ENVB 0.17
- KXIN 0.09
- MACD
- ENVB 2.34
- KXIN 0.01
- Stochastic Oscillator
- ENVB 12.20
- KXIN 29.17
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company primarily generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.